On presentation, his Hb concentration was 15.7 g/dl, platelet count 218 × 10 9 /l, and WBC count 8.2 × 10 9 /l. Laboratory tests of renal function were normal. He was treated Hemolytic uremic syndrome (HUS) has been reported in patients receiving bone marrow transplantation.
) on days −6, −5 and −4, CY (50 mg/kg) on days −3 and −2. TBI was not performed. chloride was effective. Keywords: peripheral blood stem cell transplantation;
The WBC count exceeded 1.0 × 10 9 /l by day 11. The last platelet transfusion was administered on day 14 following hemolytic uremic syndrome; vincristine; methylprednisolone; ticlopidine hydrochloride PBSCT. He did not require red cell transfusion. His course was complicated by a dermal herpes zoster infection on day 48, which was treated with acyclovir. On day 55, his serum creatinine concentration was 0.8 mg/dl and neither proIt is now clear that hemolytic uremic syndrome (HUS) may teinuria nor hematuria were present. Hb concentration was occur as a complication of BMT. Several factors are 9.2 g/dl, platelet count 71 × 10 9 /l, and WBC count reported to increase the risk of post-transplant HUS in 5.0 × 10 9 /l. He is in CR. BMT, including CsA, GVHD, TBI, and active CMV infecOn day 94 post-transplant, the Hb concentration was tion.
1 However, few reports of patients developing HUS 5.6 g/dl, platelet count 29 × 10 9 /l, and WBC count following autologous peripheral blood stem cell transplan-6.0 × 10 9 /l. The serum creatinine concentration was normal. tation (PBSCT) have been reported. This is, to our knowBone marrow examination showed a megakaryocyte count ledge, the first report of a case of HUS following autologof 30/l and a normocellular marrow with 56.4% erythroous PBSCT for malignant lymphoma. Autologous PBSCT cytes and no lymphoma cells. However, the Hb concenfor patients with hematological malignancies has been tration and platelet count gradually decreased over the folavailable as alternatives to ABMT in recent years. With the lowing 3 weeks, and lymph node enlargement recurred in increasing use of PBSCT, it is speculated that HUS followthe cervical and inguinal regions. He was readmitted to our ing autologous PBSCT will be reported with increasing frehospital on day 114 after transplantation. A biopsy speciquency. It is important to prospectively monitor patients for men from an inguinal lymph node revealed recurrence of the development of HUS as in our experience. the lymphoma. Hb concentration was 5.4 g/dl, platelet count 19 × 10 9 /l, WBC count 4.5 × 10 9 /l, and reticulocytes 4.5%. A peripheral blood smear showed RBC fragmenCase report tation. Laboratory findings were as follows: total bilirubin 0.9 mg/dl, lactate dehydrogenase 1917 U/l. Serum hapto-A 40-year-old man was diagnosed with non-Hodgkin's globin was undetectable at Ͻ12 infection was noted before the onset of HUS. It is noted that TTP/HUS may develop following some viral infecdose of 1000 mg/day was administered intravenously for 3 consecutive days; this was followed by 60 mg/day of oral tions. There is only one previous report of TTP in a patient with herpes zoster infection. 2 However, TTP occurred in prednisolone. The dose of prednisolone was tapered to 5 mg/day during the subsequent 4 weeks. His serum creatithis patient 1 week after the development of infection. In contrast, in conditioning-associated HUS, the onset nine was 225 mol/l and BUN 23.6 mmol/l on day 129 and 97 mol/l and 10.1 mmol/l, respectively, on day 150 occurred between 3 and 8 months after BMT/PBSCT.
1,3-7
Therefore, we speculate that our case also fits into the 'con- (Figure 1 ). In addition to these treatments, although six units of fresh frozen plasma (FFP) were given each day for ditioning-associated HUS' subtype. Our patient did not receive TBI. In the conditioning-asso-5 days, thrombocytopenia and microangiopathic hemolytic anemia did not resolve. On day 197, the serum creatinine ciated HUS, TBI is implicated as a predisposing factor.
1
The majority of patients with HUS after autologous and BUN increased again (249 mol/l, 14.9 mmol/l, respectively). Thus, VCR infusion and methylprednisolone BMT/PBSCT also received TBI. HUS without TBI has been reported previously in a total of nine patients followpulse therapy were resumed. VCR therapy was continued at the same dose until day 225. A total of four weekly doses ing autologous BMT/PBSCT. [3] [4] [5] [6] [7] In these patients, the chemotherapeutic agents administered during the pre-transwere administered. In addition to the VCR infusion, daily methylprednisolone was administered intravenously at a plant conditioning regimens have been implicated as contributing factors in the development of this syndrome. dose of 500 mg for 3 days. Laboratory tests of renal function improved. Moreover, bicytopenia gradually improved Among these patients, four patients had received the combination of BCNU, etoposide, Ara-C, and CY, three the same with these therapies. On day 228, the Hb concentration was 8.9 g/dl and platelet count 94 × 10 9 /l. No fragmented red combination without etoposide, and two the combination of carboplatin, CY, and thiotepa. As different schedules and cells were seen, and his serum haptoglobin increased (59 mg/dl). However, to date the enlargement of his lymph doses were used, our regimen is not directly comparable, but the combination of etoposide, CY, and carboplatin is nodes has not improved.
suspected to be a significant contributing factor in our patient.
In the HUS following BMT, early plasma exchange and Discussion infusion of FFP represent first-line treatment. started at an early stage of the disease, it might be useful. the same conditioning regimen did not develop HUS following PBSCT. In addition to the chemotherapeutic agents However, recently, it has been suggested that this syndrome administered during the conditioning regimen, other factors following BMT did not improve on these treatments. 8 Also, that predispose to this syndrome likely exist. Further studies in the post-autologous BMT/PBSCT HUS without TBI, will help to clarify these factors. seven patients received intensive FFP therapy; 3,6,7 but only one patient responded to this treatment. Successful treatment of TTP has been reported with plasmapheresis, References plasma transfusions, VCR, corticosteroids, and antiplatelet
